Salman Safdar

ABL Inc.

With a 60+ year history as a service provider to the life sciences industry, Advanced BioScience Laboratories (ABL) provides a strong core of product development expertise, GMP manufacturing, and immunological testing capabilities. Founded in 1961 as a biomedical research contractor for the federal government, ABL has made major contributions to the development and evaluation of a wide range of life-saving diagnostics, vaccines, and therapeutics designed to combat the world's most challenging diseases. We partner with our clients to support advancement of their candidate vaccines and therapeutics through preclinical and clinical development. We aim to be a seamless extension of our clients' team – helping them advance today's ideas into tomorrow's medicines. ABL is a subsidiary of the Institut Mérieux, with sites in France and the United States. As a comprehensive Immunology CRO, our services encompass the full scope of immunological response to support advancement of therapeutics and vaccines from discovery through preclinical and clinical development. Through our work over the years, ABL has developed a broad range of Immunological, virological and PCR-based assays across multiple platforms to support preclinical and clinical studies for a variety of indications and treatments, including infectious diseases, oncology, neurodegenerative disorders, and cell & gene therapies. On the CDMO side, ABL specializes in the development and manufacturing of GMP cell banks and viral vectors from early stage to market, and contributes to the success of its clients' immunotherapy innovations, including gene therapies, immunotherapies, viral vaccines, recombinant protein vaccines, and more. ABL's CDMO services include bulk drug substance, fill/finish of drug products, process and assay development, and bioanalytical testing.